Skip to main content
Figure 12 | BMC Cancer

Figure 12

From: Preferential antitumor effect of the Src inhibitor dasatinib associated with a decreased proportion of aldehyde dehydrogenase 1-positive cells in breast cancer cells of the basal B subtype

Figure 12

Effects of dasatinib and/or Eto on the proportion of ALDH1-positive cells in BT-474 cells. The cells were treated with 0.1 μM Eto and/or 0.1 μM dasatinib for two days, and ALDH1-positive cells were measured by the immunocytochemical analysis as described in the Materials and Methods. Dasatinib slightly increased the proportion of ALDH1-positive cells in BT-474 cells. *P < 0.05.

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us